SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending as CEO Dr. Patrick Soon-Shiong's high-profile media appearances highlight the company's revolutionary cancer treatments and AI-driven cell therapy, sparking community enthusiasm and frustration over perceived regulatory roadblocks. Investors are closely watching patient testimonials and discussing a potential short squeeze, anticipating significant market movement.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending with high community engagement ahead of the 4/20 cannabis holiday, as supporters highlight its robust culture and claim it's outperforming traditional cannabis stocks. While many advocate for its long-term potential as a "culture coin," others warn of its "pump and dump" characteristics.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing a significant surge driven by strong Q4 results and upbeat guidance, fueled by accelerating demand for its 400G and 800G transceivers from hyperscale data centers in the booming AI sector. While many anticipate substantial future growth and a potential short squeeze, the community is also actively debating its current valuation and the implications of a recent $250 million stock offering.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending sharply higher amid intensifying geopolitical tensions in the Middle East, with the community actively discussing potential military action in Iran and rising crude oil prices, recalling the stock's historical volatility during past conflicts.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Space and Airborne Systems, Integrated Mission Systems, Communication Systems, and Aerojet Rocketdyne. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne and cyber domains. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land and sea domains. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris Technologies is trending due to a significant Department of War investment in its Missile Solutions business ahead of a planned 2026 IPO, coupled with major contract wins in missile tracking and defense aircraft, while community discussions balance excitement over strategic partnerships and analyst upgrades against recent price volatility.

Green Satoshi Token

Green Satoshi Token (GSTSOL) is trending amidst a notable increase in volume and a perceived breakout, igniting strong community bullishness as many anticipate a significant "alt season" pump for the low-cap crypto despite historical frustrations.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending after its Q4 earnings beat and strong cash flow were overshadowed by widespread investor frustration with CEO Peter Greenleaf's perceived lack of transparency. Community discussions are heavily focused on the ongoing delays and secrecy surrounding the AUR200 pipeline indications, intensifying speculation of a potential acquisition for the undervalued biotech.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is generating significant discussion as a bellwether for the U.S. market, with investors observing strong inflows and its proximity to all-time highs. The community is weighing these positive signals against prevailing political and economic uncertainties, prompting ongoing debate about diversification and market direction.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending after its Q4 earnings beat resulted in a significant stock price drop, sparking widespread community frustration over perceived management communication issues and accelerated dilution from stock-based compensation. Investors are weighing the company's muted 2026 growth-focused guidance and high short interest against strong underlying performance and new OEM partnerships.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

Satellos Bioscience (MSLE) is trending as the biotech community eagerly anticipates upcoming clinical data for its Duchenne Muscular Dystrophy (DMD) oral therapy, SAT-3247, following its recent Nasdaq uplisting and capital raise. While proponents highlight promising preclinical and early clinical biomarker results suggesting revolutionary muscle regeneration, skeptics raise concerns about past dilutions and the high attrition rate of early-stage DMD drug development.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Vanguard Russell 1000 Growth ETF (VONG) Be on Your Investing Radar?

<ul class="summary-bullets"><li>DraftKings in Q4 reported revenue of $1,989 million, an increase of 43%, compared to the same period in 2024.</li><li>The increase in the Q4 2025 revenue was driven primarily by continued healthy customer engagement, efficient acquisition of new customers, and higher Sportsbook net revenue margin.&nbsp;</li></ul>DraftKings shares nosedived in after-market hours on Thursday after its full year 2026 forecast fell short of expectations and disappointed investors.&nbsp;It said it is expecting fiscal year 2026 revenue to be in the range of $6.5 billion to $6.9 billion, compared to analysts’ estimates of $7.3 billion, as per data from fiscal.ai.&nbsp;“Our core business is strong as we enter 2026,” said Jason Robins, DraftKings’ Chief Executive Officer and Co-founder. “We also see a massive, incremental opportunity in DraftKings Predictions. We plan to deploy growth capital to build the best customer experience in Predictions, and acquire millions of customers. We have the playbook to execute and win.”<h2 class="st-heading-2">Q4 Highlights</h2>DraftKings for the three months ended December 31, 2025, reported revenue of $1,989 million, an increase of $596 million, or 43%, compared to $1,393 million during the same period in 2024.The increase in the company’s fourth quarter 2025 revenue was driven primarily by continued healthy customer engagement, efficient acquisition of new customers, and higher Sportsbook net revenue margin, according to the company.&nbsp;“We closed 2025 on a high note. Fourth quarter revenue increased 43% year-over-year and we achieved records for revenue and Adjusted EBITDA,” said Robins.&nbsp;DraftKings’ Average Revenue per MUP (“ARPMUP”) was $139 in the fourth quarter of 2025, representing a 43% increase compared to the same period in 2024. The increase was primarily due to higher net revenue margin across both Sportsbook and iGaming.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DKNG trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user said that the stock will fall further to $14 on Friday.<stembedurl>https://stocktwits.com/viji998/message/644864290</stembedurl>Another user said that they are buying the stock despite noting that revenue guidance is bad.&nbsp;<stembedurl>https://stocktwits.com/undercat22/message/644863726</stembedurl>Shares in the company have fallen 50% over the past year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/coinbase-stock-rises-despite-posting-surprise-q4-net-loss/cZRTzudR4r6">Coinbase Stock Rises After-Hours Despite Posting Surprise Net Loss In Q4</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the logo of DraftKings Inc. is displayed on a smartphone screen. 

DraftKings Stock Plummeted 15% After Hours –What Is Driving Such A Selloff?

DraftKings said it is expecting fiscal year 2026 revenue to be in the range of $6.5 billion to $6.9 billion, compared to analysts’ estimates of $7.3 billion, as per data from fiscal.ai. 

Equity

DraftKings said it is expecting fiscal year 2026 revenue to be in the range of $6.5 billion to $6.9 billion, compared to analysts’ estimates of $7.3 billion, as per data from fiscal.ai. 


Here's How Much You Would Have Made Owning Vanguard Russell 1000 Growth ETF Stock In The Last 15 Years

Shares of VONG Now Oversold

In trading on Tuesday, shares of the Vanguard Russell 1000 Growth ETF (Symbol: VONG) entered into oversold territory, changing hands as low as $117.90 per share. We define oversold territory using...

VONG ETF Factor Report

Below is Validea's ETF fundamental report for Vanguard Russell 1000 Growth ETF (VONG). The report looks at VONG's exposure to the major investing factors including value, quality, momentum and low...

Detailed Fundamental Analysis - VONG

Viking Therapeutics has faced a tough start to 2025, with its shares down more than 22% as of Thursday’s close.On Wednesday, the San Diego-based clinical-stage biopharmaceutical company reported a fourth-quarter loss of $0.32 per share, which was wider than the expected $0.27.&nbsp;Viking is still in the development phase and has yet to generate revenue, a common scenario for small- and mid-cap biotech startups.As of Dec. 31, 2024, Viking had $903 million in cash and investments, which it says will help it achieve critical clinical milestones, including completing Phase 3 trials for its subcutaneous version of VK2735, an obesity therapy.In a recent Stocktwits poll, retail traders were asked for their stock price expectations for Viking by the end of 2025.&nbsp;A significant 35%&nbsp;of the poll respondents believe the stock will close below $30, while 32% expect it to rise above $80, a level last seen in late October.&nbsp;Meanwhile, 18% anticipate the stock will end the year between $50 and $80, and 15% see it landing between $30 and $50.<figure class="image"><img style="aspect-ratio:1306/650;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/VKTX_price_prediction_Stocktwits_poll_on_Feb_7_30c9d66fd7.png" alt="VKTX price prediction Stocktwits poll on Feb 7.png" width="1306" height="650"><figcaption>VKTX price prediction Stocktwits poll on Feb 7</figcaption></figure>In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735, a Phase 1 trial of an oral tablet form of VK2735, a Phase 2b study for VK2809 to treat metabolic steatohepatitis (MASH) and fibrosis, and a Phase 1b study of VK0214 for X-linked adrenoleukodystrophy.&nbsp;However, there is growing concern over increased competition in the weight-loss drug market, with Novo Nordisk and Eli Lilly dominating the sector.William Blair and Oppenheimer analysts have speculated that Viking could be an acquisition target for a larger company.&nbsp;This premise gained momentum earlier this week when Novartis CEO Vas Narasimhan revealed that the company is seeking next-generation obesity drug candidates.&nbsp;Shares of Viking spiked on the news, despite Novartis’s own obesity program being in the early stages of development, with no human clinical trials yet.Retail traders on Stocktwits are also bullish on the possibility of a merger or acquisition, especially as Viking’s shares have fallen by over 50% in the past three months.&nbsp;Notably, short interest on Viking has surged from 11.9% in mid-November to over 18% by the end of January.Wall Street’s average price target for Viking is $105.73, representing an upside of more than 230% from current levels.Morgan Stanley analysts, in a note on Thursday, said that after meeting with Viking's management, the company remains confident in securing a commercial manufacturing contract for subcutaneous VK2735, supporting a multibillion-dollar opportunity.The brokerage reiterated its 'Overweight' for the stock and its price target of $105.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Viking Therapeutics Stock Down Over 20% In 2025: Retail Traders Predict Where It Could End The Year

In 2024, Viking reported positive results from four different clinical trials, including a Phase 2 study for subcutaneous VK2735 and a Phase 1 trial of an oral tablet form of VK2735 to treat obesity.

Vanguard Group, Inc. - Vanguard Russell 1000 Growth Index ETF

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

VONG
Vanguard Russell 1000 Growth Index ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest VONG News

VONGVanguard Russell 1000 Growth Index ETF